RT Journal Article
SR Electronic
T1 Amyloid and tau PET in relation to longitudinal change in subjective cognitive complaints among cognitively normal individuals
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.25.24314211
DO 10.1101/2024.09.25.24314211
A1 Bannerjee, Alisa
A1 Elkins, Wendy
A1 Resnick, Susan M.
A1 Bilgel, Murat
YR 2024
UL http://medrxiv.org/content/early/2024/09/26/2024.09.25.24314211.abstract
AB Background and Objectives Subjective cognitive complaints often precede declines in objective measures of cognitive performance and may facilitate the early diagnosis of cognitive impairment. This study examined whether amyloid and tau pathology are associated with level and longitudinal change in subjective cognitive complaints among cognitively normal individuals, and compared these associations to those observed with objective neuropsychological measures of verbal episodic memory performance.Methods Amyloid and tau pathology were measured by 11C-Pittsburgh compound B (PiB) and 18F-flortaucipir (FTP) PET scans, respectively. FTP PET regions of interest (ROIs) included the entorhinal cortex, hippocampus, parahippocampal gyrus, and inferior temporal gyrus. Subjective cognitive complaints were assessed using the Cognitive Failures Questionnaire (CFQ). California Verbal Learning Test (CVLT) immediate and long-delayed free recall scores were used to quantify objective memory performance. We examined the association of PET measures with rates of change in CFQ and verbal memory within 5 years of the PET scans using linear mixed effects models.Results We analyzed data for 92 cognitively normal participants in the Baltimore Longitudinal Study of Aging (BLSA). In analyses that included both amyloid positivity and regional tau burden as predictors greater parahippocampal tau standardized uptake value ratio (SUVR) was associated with higher CFQ, indicating greater subjective cognitive complaints (estimate = 0.178, SE = 0.0821, p = 0.033). Greater entorhinal tau SUVR corresponded to an attenuated increase in CFQ over time (estimate = -0.064, SE = 0.0296, p = 0.035), whereas greater hippocampal tau SUVR was associated with a steeper longitudinal decline in memory (estimate = -0.0293, SE = 0.0135, p = 0.032).Discussion Individuals with higher levels of tau pathology may experience greater levels of subjective cognitive complaints. Such associations are detectable among cognitively normal individuals even in the absence of marked neuropathology-associated differences in neuropsychological assessments of verbal episodic memory, suggesting that subjective cognitive complaints may serve as early indicators of accumulating cerebral tau pathology.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the Intramural Research Program of the National Institute on Aging, NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research protocols were conducted in accordance with United States federal policy for the protection of human research subjects contained in Title 45 Part 46 of the Code of Federal Regulations (45 CFR 46), approved by local institutional review boards (IRB) and the National Institutes of Health, and all participants gave written informed consent at each visit .I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes